Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

Table 2 Studied miRNA associations with different parameters in patients with hepatocellular carcinoma

	miRNA-326	miRNA-511	miRNA-424
Gender
Male 48 (68.6%)	33.6 (11.3-157.4)	1.1 (0.4-3.4)	5.4 (3.2-10.4)
Females 22 (31.4%)	42.3 (11.9-168.2)	1.1 (0.4-3.4)	4.4 (1.9-8.3)
P value	0.7	0.8	0.3
Smoker
No 56 (80.0%)	27.4 (8.4-159.0)	1.1 (0.3-2.7)	5.4 (2.9-10.6)
Yes 14 (20.0%)	67.0 (28.0-177.0)	1.2 (0.7-5.9)	4.1 (2.7-7.0)
P value	0.3	0.3	0.3
Diabetes mellitus
No 52 (74.3%)	29.4 (9.1- 119.1)	0.9 (0.3-2.5)	4.6 (2.6-9.0)
Yes 18 (25.7%)	70.4 (16.6- 218.4)	1.5 (0.9-5.1)	6.5 (4.1-13.7)
P value	0.1	0.08	0.04a
Child grade
A 58 (82.9%)	64.4 (15.3-177.0)	1.2 (0.4-3.8)	5.1 (3.0-10.3)
B 11 (15.7%)	16.1 (4.1-110.7)	0.9 (0.0-1.4)	5.2 (2.6-11.9)
C 1 (1.4%)	5.7 (5.7-5.7)	0.03 (0.03-0.03)	0.9 (0.9-0.9)
P value
B vs A
C vs A	0.03a	0.1	0.7
C vs B	0.2	0.1	0.1
	0.7	0.3	0.3
HCC stages
Early	32.0 (7.5-121.0)	1.0 (0.3-2.6)	4.5 (2.3-8.0)
Intermediate	69.8 (16.1-185.0)	1.4 (0.6-4.6)	5.3 (3.9-13.2)
Late	26.2 (14.5-179.8)	0.9 (0.1-2.9)	5.9 (2.5-10.1)
P value
Intermediate vs Early	0.2	0.1	0.04a
Late vs Early	0.6	0.8	0.5
Late vs Intermediate	0.7	0.2	0.6
Performance status
0; 43 (61.4%)	64.4 (15.8-153.3)	1.2 (0.5-3.5)	5.7 (3.1-10.2)
1; 24 (34.3%)	18.9 (7.1-184.5)	0.6 (0.0-2.5)	4.0 (1.5-10.4)
2; 2 (2.9%)	7.2 (0.5-7.8)	3.1 (0.4-3.5)	5.3 (4.8-5.5)
3; 1 (1.4%)	160.9 (160.9- 160.9)	9.6 (9.6-9.6)	22.0 (22.0-22.0)
P value	0.2	0.2	0.2

Studied miRNAs are represented as Median with Interquartile range (25% -75%), the data were analyzed by Mann-Whitney U test except for the Studied miRNAs associations with Performance status which is analysed by the Kruskal Wallis Test. HCC: Hepatocellular carcinoma.

^aP value < 0.05 is significant.